Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Enablex (darifenacin)
- pilocarpine
Interactions between your drugs
pilocarpine darifenacin
Applies to: pilocarpine, Enablex (darifenacin)
GENERALLY AVOID: Anticholinergic agents and other agents with significant anticholinergic activity (e.g., clozapine, class IA antiarrhythmics especially disopyramide) may antagonize the effects of direct-acting cholinergic agents such as bethanechol, carbachol, cevimeline, and pilocarpine. This interaction is sometimes desirable and is the basis for using atropine in the treatment of excessive muscarinic side effects and cholinergic crisis induced by cholinergic overdose. Conversely, cholinergic agents may also counteract the pharmacologic effects of anticholinergic agents and other agents that rely partially on their anticholinergic activity for therapeutic effects (e.g., some antiparkinsonian and antiemetic/antivertigo agents). The mechanism of interaction involves opposing pharmacodynamic action on muscarinic receptor sites.
MANAGEMENT: It may be appropriate to avoid concomitant use of anticholinergic agents and cholinergic agents, depending on the needs of the patient. If concurrent use is necessary, the patient should be monitored for reduced pharmacologic effects of both drugs.
References (2)
- Benjamin KW (1979) "Toxicity of ocular medications." Int Ophthalmol Clin, 19, p. 199-255
- "Product Information. Salagen (pilocarpine)." Boehringer-Ingelheim
Drug and food interactions
darifenacin food
Applies to: Enablex (darifenacin)
The consumption of grapefruit juice may be associated with increased plasma concentrations of darifenacin. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. The clinical significance is unknown.
References (1)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Gemtesa
Gemtesa (vibegron) is used to treat overactive bladder symptoms (OAB) in adults or men taking ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
Estrace
Estrace (estradiol) is used to treat symptoms of menopause such as hot flashes and vaginal dryness ...
VESIcare
Vesicare is used to treat symptoms of overactive bladder such as incontinence and frequent ...
Detrol
Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and ...
Ditropan
Ditropan XL (oxybutynin extended release) is used to treat the symptoms of overactive bladder ...
Estradiol Patch
Estradiol Patch is used for atrophic urethritis, atrophic vaginitis, breast cancer, palliative ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.